Tempero Bio Secures $70M to Advance TMP-301 for Phase 2 Trials
Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The financing...